EUVIMEDEUVIMED entdecken
Crossref

NRG1 Fusion–Driven Pancreatic Cancer: Real-World Detection Across a Japanese National Database and International Genomic Datasets, With an Illustrative RNA-Confirmed Case

Makoto Sugimori, Akane Hirotani, Yuichi Suzuki, Haruka Tanaka, Masanori Oshi, Yukiko Sasahara, Natsuko Takeda, Satoshi Nozaki, Haruo Miwa, Akito Nozaki, Kazuya Sugimori, Manabu Morimoto und 3 weitere

JCO Oncology Advances · 2026-10 · 3 (4)

DOI: 10.1200/oa-26-00070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Makoto Sugimori und 14 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

NRG1 fusions drive oncogenic HER2/HER3 signaling and define a rare, clinically actionable subset of pancreatic cancer (PC). Zenocutuzumab, a bispecific HER2/HER3-targeting antibody, has shown antitumor activity in NRG1 fusion–positive PC. However, real-world detection of NRG1 fusions may vary according to assay design, target coverage, and the incorporation of RNA sequencing. Materials and Methods We evaluated the observed frequencies and clinicogenomic features of reported NRG1 fusions across the Japanese national Comprehensive genomic profiling (CGP) database and international public CGP data sets spanning five CGP platforms (total N = 12,647). We additionally describe an illustrative PC case in which an NRG1 fusion was confirmed only after RNA-based reanalysis.

Results

NRG1 fusions were identified in 7 of 12,647 cases (0.055%; 0%–0.339% across platforms), and most were KRAS wild-type (6/7). The index case, a 41-year-old man with invasive adenocarcinoma associated with intraductal tubulopapillary neoplasm, showed no definitive pathogenic alterations on the initial CGP report. Targeted reanalysis prompted by an 8p copy-number abnormality identified an in-frame APP::NRG1 fusion by RNA sequencing, which was subsequently confirmed by fusion-specific reverse-transcription polymerase chain reaction.

Conclusion

NRG1 fusions in PC are rare yet clinically actionable. RNA-inclusive workflows should be considered in selected cases, particularly those without a canonical KRAS alteration.

Zitieren

APA

Sugimori, M., Hirotani, A., Suzuki, Y., Tanaka, H., Oshi, M., Sasahara, Y., Takeda, N., Nozaki, S., Miwa, H., Nozaki, A., Sugimori, K., Morimoto, M., Kudo, M., Fujii, S., & Maeda, S. (2026). NRG1 Fusion–Driven Pancreatic Cancer: Real-World Detection Across a Japanese National Database and International Genomic Datasets, With an Illustrative RNA-Confirmed Case. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00070

Vancouver

Sugimori M, Hirotani A, Suzuki Y, Tanaka H, Oshi M, Sasahara Y, et al. NRG1 Fusion–Driven Pancreatic Cancer: Real-World Detection Across a Japanese National Database and International Genomic Datasets, With an Illustrative RNA-Confirmed Case. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00070

BibTeX
@article{Sugimori2026,
  author = {Sugimori, Makoto and Hirotani, Akane and Suzuki, Yuichi and Tanaka, Haruka and Oshi, Masanori and Sasahara, Yukiko and Takeda, Natsuko and Nozaki, Satoshi and Miwa, Haruo and Nozaki, Akito and Sugimori, Kazuya and Morimoto, Manabu and Kudo, Makoto and Fujii, Satoshi and Maeda, Shin},
  title = {NRG1 Fusion–Driven Pancreatic Cancer: Real-World Detection Across a Japanese National Database and International Genomic Datasets, With an Illustrative RNA-Confirmed Case},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.1200/oa-26-00070}
}
Kostenlos starten →